调肝理脾法对非酒精性脂肪性肝病大鼠模型肠黏膜Toll样受体4、occludin表达的影响

陈瑞琳; 申青艳; 牛柯敏; 杨仲婷; 殷秀雯; 李雪; 周滔; 陈誩; 危北海

doi:10.3969/j.issn.1001-5256.2019.10.024

调肝理脾法对非酒精性脂肪性肝病大鼠模型肠黏膜Toll样受体4、occludin表达的影响

DOI: 10.3969/j.issn.1001-5256.2019.10.024

1. 北京中医药大学北京中医临床医学院
2. 首都医科大学附属北京中医医院

基金项目:

国家重点研发计划(2018YFC1704100,2018YFC1704102)；第四批全国中医(临床、基础)优秀人才研修项目(国中医药人教发〔2017〕24号)；北京市卫生系统高层次卫生技术人才培养计划(2015-3-114)；北京市属医院科研培育计划项目(PZ2016021)；

详细信息

中图分类号: R259;R-332
计量
- 文章访问数: 1110
- HTML全文浏览量: 51
- PDF下载量: 218
- 被引次数: 6
出版历程
- 收稿日期: 2019-05-27
- 出版日期: 2019-10-20

Effect of the liver-regulating and spleen-strengthening method on the expression of Toll-like receptor 4 and occludin in the intestinal mucosa of rats with nonalcoholic fatty liver disease

Clinical School of Traditional Chinese Medicine,Beijing University of Chinese Medicine

Research funding:

摘要

摘要:
目的观察调肝理脾法对高脂高糖饲料诱导的非酒精性脂肪性肝病大鼠模型肠黏膜屏障Toll样受体（TLR） 4、occludin的影响。方法将50只SD雄性大鼠随机分为正常组、模型组、调肝理脾组、调肝组和理脾组,并用高脂高糖饲料喂养4周诱导大鼠非酒精性脂肪性肝病模型,观察各组肝脏脂肪变性程度,肝功能变化及肠黏膜紧密连接蛋白occludin、肠道上皮TLR4的表达情况。计量资料多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验。结果与正常组相比,模型组肝脏呈现脂肪变性;血清ALT、AST水平均显著升高（P值均<0. 05）,肠黏膜上皮细胞紧密连接蛋白occludin的表达降低,肠道上皮TLR4表达增加。与模型组相比,各治疗组脂肪变性程度均有减轻; occludin的表达均有增加;肠道上皮TLR4表达均有降低。各治疗组中,调肝理脾组脂肪变性程度最轻;血清ALT、AST水平降低更显著,与模型组比较差异均有统计学意义（P值均<0. 05）; occludin及TLR4的表达量变化更明显。结论调肝理脾法通过上调肠黏膜上皮细胞紧密连接蛋白occludin的表达,降低肠道TLR4的表...
- 非酒精性脂肪性肝病 /
- 调肝理脾法 /
- 肠黏膜 /
- 大鼠,Sprague-Dawley
Abstract:
Objective To investigate the effect of the liver-regulating and spleen-strengthening method on the expression of Toll-like receptor 4(TLR4) and occludin in the intestinal mucosal barrier of rats with nonalcoholic fatty liver disease(NAFLD) induced by high-fat and high-sugar diet. Methods A total of 50 male Sprague-Dawley rats were randomly divided into normal group,model group,liver-regulating and spleen-strengthening group,liver-regulating group,and spleen-strengthening group. A rat model of nonalcoholic steatohepatitis was established by high-fat and high-sugar diet for four weeks. The five groups were observed in terms of the degree of hepatic steatosis,the change in liver function,and the expression of the tight junction protein occludin in the intestinal mucosa and TLR4 in the intestinal epithelium. A one-way analysis of variance was used for comparison between multiple groups,and the least significant difference t-test was used for further comparison between two groups. Results Compared with the normal group,the model group showed hepatic steatosis and had significant increases in the serum levels of alanine aminotransferase(ALT) and aspartate aminotransferase(AST)(P<0. 05),as well as a reduction in the expression of the tight junction protein occludin in intestinal epithelial cells and an increase in the expression of TLR4 in the intestinal epithelium. Compared with the model group,the three treatment groups had a significant reduction in the degree of steatosis,a significant increase in the expression of occludin,and a significant reduction in the expression of TLR4 in the intestinal epithelium. Among the three treatment groups,the liver-regulating and spleen-strengthening group had the lowest degree of steatosis and significantly greater reductions in the serum levels of ALT and AST than the model group(P < 0. 05),as well as significantly greater changes in the expression of occludin and TLR4. Conclusion The liver-regulating and spleen-strengthening method can improve intestinal mucosal barrier function by increasing the expression of the tight junction protein occludin in intestinal epithelial cells and reducing the expressionof TLR4 in the intestine,with a better clinical effect than the liver-regulating method or the spleen-strengthening method alone.
- non-alcoholic fatty liver disease /
- method of regulating liver and spleen /
- intestinal mucosa /
- rats,Sprague-Dawley

HTML全文

参考文献(23)

[1] LI Z,XUE J,CHEN P,et al. Prevalence of nonalcoholic fatty liver disease in mainland of China:A meta-analysis of published studies[J]. J Gastroenterol Hepatol,2014,29(1):42-51.

[2] YU Y,CAI J,SHE Z,et al. Insights into the epidemiology,pathogenesis,and therapeutics of nonalcoholic fatty liver diseases[J]. Adv Sci(Weinh),2019,6(4):1801585.

[3] AKSHAY S,HSU JW,MANKA P,et al. Role of the circadian clock in the metabolic syndrome and nonalcoholic fatty liver disease[J]. Dig Dis Sci,2018,63(12):3187-3206.

[4] MAREO P,LUCA P,PIETRO V. Gut-liver axis derangement in non-alcoholic fatty liver disease[J]. Children,2017,4(8):66-84.

[5] LI JX,WANG YL,GUO Y,et al. Clinical effect of traditional Chinese medicine treatment in nonalcoholic fatty liver disease[J]. Chin J Integr Trad West Med Dig,2017,25(11):801-804.(in Chinese)李军祥,王允亮,郭一,等.中医药治疗非酒精性脂肪性肝病专题笔谈[J].中国中西医结合消化杂志,2017,25(11):801-804.

[6] CHEN J,FENG CL,NIE ZY,et al. Effect of Shugan Xiaozhi decoctionⅢcapsule on the CYP2E1 in the rat with non-alcoholic fatty liver disease[J]. J Changchun Univ Chin Med,2017,33(3):351-354.(in Chinese)陈进,冯崇廉,聂钊源,等.疏肝消脂Ⅲ方胶囊对非酒精性脂肪肝大鼠CYP2E1基因表达的影响[J].长春中医药大学学报,2017,33(3):351-354.

[7] ZHOU T,ZHANG SS,YU Q. Clinical cohort study on non-alcoholic fatty liver disease by regulating liver and spleen[J]. Beijing J Tradit Chin Med,2013,32(6):403-405.(in Chinese)周滔,张声生,郁强.调肝理脾法治疗非酒精性脂肪肝的临床队列研究[J].北京中医药,2013,32(6):403-405.

[8] YAN X,ZHOU T,TAO Y,et al. Salvianolic acid B attenuates hepatocyte apoptosis by regulating mediators in death receptor and mitochondrial pathways[J]. Exp Biol Med(Maywood),2010,235(5):623-632.

[9] XIA F,ZHOU BJ. Role of gut-liver axis dysfunction in pathogenesis of non-alcoholic fatty liver disease:Implications for treatment strategies[J]. World Chin J Dig,2018,26(24):1439-1447.(in Chinese)夏凡,周本杰.肠-肝轴功能紊乱在非酒精性脂肪肝病发病机制中的作用及相关治疗策略[J].世界华人消化杂志,2018,26(24):1439-1447.

[10] DAI X,LYU ZS. Role of gut barrier function in the pathogenesis of nonalcoholic fatty liver disease[J]. World Chin J Dig,2012,20(8):656-661.(in Chinese)戴鑫,吕宗舜.肠道屏障功能在非酒精性脂肪性肝病发病机制中的作用[J].世界华人消化杂志,2012,20(8):656-661.

[11] MIN Y,QIMENG W,YUANHANG M,et al. Aryl hydrocarbon receptor activation modulates intestinal epithelial barrier function by maintaining tight junction integrity[J]. Int J Biol Sci,2018,14(1):69-77.

[12] CHENG J,LI FL,ZHANG B,et al. Effects of high fat diet on intestinal flora and serum LPS levels in NAFLD model rats[J].J Anhui Med Univ,2017,52(9):1341-1345.(in Chinese)程靖,李枫林,张宝,等.高脂饮食对NAFLD模型大鼠肠道菌群及血清LPS水平的影响[J].安徽医科大学学报,2017,52(9):1341-1345.

[13] LI BL,XIE BW,HU PY,et al. Research advances in the association between nonalcoholic fatty liver disease and intestinal microecology[J]. J Pract Med,2018,34(1):156-158.(in Chinese)李蓓蕾,谢博文,胡朋言,等.非酒精性脂肪肝与肠道微生态关系的研究进展[J].实用医学杂志,2018,34(1):156-158.

[14] BRUN P,CASTAGLIUOLO I,DI LV,et al. Increased intestinal permeability in obese mice:New evidence in the pathogenesis of nonalcoholic steatohepatitis[J]. Am J Physiol Gastrointest Liver Physiol,2007,292(2):518-525.

[15] SNCHEZ de MEDINA F,ROMERO-CALVO I,MASCARAQUE C,et al. Intestinal inflammation and mucosal barrier function[J]. Inflammatory Bowel Diseases,2014,20(12):2394-2404.

[16] KOUICHI M,EKIHIRO S,HIROHIDE O,et al. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease[J]. Gastroenterol Res Pract,2010,2010:1-9.

[17] CAPIRALLA H,VALERIE V,ZHAO H,et al. Resveratrol mitigates lipopolysaccharide-and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade[J]. J Neurochem,2012,120(3):12.

[18] GU J,LIU JB,HUO WZ. BBI blocks LPS-mediated inhibitory effect on tight junction protein of intestinal epithelial cells[J].Chin J Infec Contl,2018,17(3):185-190.(in Chinese)古俊,刘金彪,霍文哲. BBI阻断LPS对肠道上皮细胞间紧密连接蛋白的抑制作用[J].中国感染控制杂志,2018,17(3):185-190.

[19] CANI PD,AMAR J,IGLESIAS MA,et al. Metabolic endotoxemia initiates obesity and insulin resistance[J]. Diabetes,2007,56(7):1761-1772.

[20] Special Committee of Digestive System Disease,Chinese Association of Integrative Medicine. Consensus statements on integrated traditional Chinese and Western medicine diagnosis and treatment of nonalcoholic fatty liver disease(2017)[J].Chin J Integr Trad West Med Dig,2017,25(11):805-811.(in Chinese)中国中西医结合学会消化系统疾病专业委员会.非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2017,25(11):805-811.

[21] WEI GC,HE JY. Traditional Chinese medicine intervention to nonalcoholic fatty liver disease based on physique identification[J]. J Changchun Univ Chin Med,2018,34(3):518-521.(in Chinese)魏功昌,何瑾瑜.中医体质辨识治疗非酒精性脂肪性肝病[J].长春中医药大学学报,2018,34(3):518-521.

[22] Branch of Gastrointestinal Diseases,China Association of Chinese Medicine. Consensus statements on TCM diagnosis and treatment of nonalcoholic fatty liver disease(2009,Shenzhen)[J]. Chin J Integr Trad West Med Dig,2010,18(4):276-279.(in Chinese)中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗共识意见(2009,深圳)[J].中国中西医结合消化杂志,2010,18(4):276-279.

[23] TAO L,ZHANG SS. Clinical effect of the liver-soothing,turbid pathogen-eliminating,and blood circulation-activating method in treatment of nonalcoholic simple fatty liver:An analysis of 30 cases[J]. China J Tradit Chin Med Pharma,2008,23(6):552-553.(in Chinese)陶琳,张声生.疏肝化浊活血法治疗非酒精性单纯性脂肪肝30例的临床观察[J].中华中医药杂志,2008,23(6):552-553.

施引文献

期刊类型引用(5)

1.	温惠玲，梁艳，邓昕. 苓桂术甘汤联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝病临床研究. 河南中医. 2022(11): 1639-1643 . 百度学术
2.	林军，苏林红，叶小丹，朱小区. 基于“脾虚浊凝”理论探讨非酒精性脂肪性肝病辨治思路. 浙江中医药大学学报. 2022(10): 1156-1160 . 百度学术
3.	李枝锦，吴平财，周山. 调肝运脾化浊方联合电针治疗非酒精性脂肪肝. 长春中医药大学学报. 2021(01): 103-107 . 百度学术
4.	黄祖鸿，石清兰，柏文婕，韦华柱，莫展进，邓霖霖. 毛德文教授运用“调肝理脾”法治疗慢性肝病经验总结. 陕西中医. 2021(08): 1112-1114+1119 . 百度学术
5.	夏冬丽，魏莎，杨丹. 沉默miR-375对非酒精性脂肪性肝病发生发展的作用及机制探究. 国际消化病杂志. 2020(03): 186-189+202 . 百度学术